A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic뮤신-1 감소 화합물에 대한 고함량 검사를 통해 포스타마티닙이 COVID-19 대유행 기간 동안 급성 폐 손상에 대한 신속한 용도 변경을 위한 후보로 확인됨Article Published on 2020-06-302022-09-11 Journal: bioRxiv [Category] 비임상, [키워드] acute lung injury apical surface approved ARDS arising biochemical marker breath candidate Cell cell surface clinical development clinical outcomes clinical trial clinical trials Compound content COVID-19 pandemic distress drug drug candidate Drug repurposing Efficacy elevated epithelial cells expressed fostamatinib identify Immune thrombocytopenia inhibitor Lung disease lung epithelial cell Lung epithelial cells Lung injury membrane-bound mouse model MUC1 mucin mucosal pandemic pandemic spread Patient patients with COVID-19 predict promoted Protein provide R788 Rapid rationale reduce reduced repurposing required respiratory distress Respiratory distress syndrome reveal SARS-CoV-2 SARS-COV-2 infection Screen spleen Spread Stage standing up SYK syndrome the cell thrombocytopenia Treatment tyrosine [DOI] 10.1101/2020.06.30.180380 PMC 바로가기 [Article Type] Article